Closer to Treatment Isn't the Same as Getting It

Eight million Medicaid records across ten states, mapped against every buprenorphine prescriber, methadone clinic, and naltrexone provider within reach — and the number of people who actually started one of those medications barely moved. That is the headline result buried in a new JAMA Health Forum study that a lot of state health departments were hoping would come out differently, since “recruit more prescribers” has been the go-to fix for the opioid treatment gap for a decade.

Being able to reach a prescriber and actually taking the medicine turned out to be two different problems with two different solutions.

The researchers — Coleman Drake, Michael Sharbaugh, Dylan Nagy, and colleagues — tracked 8,081,899 Medicaid enrollees in Delaware, Kentucky, Maine, Maryland, Michigan, North Carolina, Pennsylvania, Tennessee, Virginia, and West Virginia, states that together hold a huge share of the country’s opioid overdose burden. About 472,409 of those enrollees, 5.8%, carried a diagnosis of opioid use disorder. The team then measured how many buprenorphine, methadone, and naltrexone providers sat within a reasonable radius of each person and checked whether living somewhere with more of them predicted more people actually filling a prescription. For buprenorphine — the medication most people with opioid use disorder are prescribed — living near more prescribers barely nudged use at all. Methadone and naltrexone showed a real but small effect, and only for non-Hispanic White enrollees: about a 0.99 percentage-point bump in methadone use where availability was above the state median. Non-Hispanic Black and Hispanic enrollees saw no comparable gain, even in the exact same high-availability areas. The honest read here has real limits attached: this is ten states, all Medicaid, mostly Appalachian and mid-Atlantic in character, so it isn’t proof that geography never matters anywhere. What it shows is that in a huge, real-world Medicaid population, simply building out the map of providers did not close the racial gap in who gets treated, and for the most-used medication, it barely closed any gap at all. Distance to a clinic, it turns out, is just one filter among many — insurance friction, stigma from the last bad experience with a doctor, transportation that a map can’t capture, work schedules — and none of those get fixed by adding another buprenorphine prescriber to a strip mall.

If proximity doesn’t predict who gets treatment, something else is shaping what actually reaches people — sometimes literally, in a kitchen cabinet. A Journal of Addiction Medicine study led by Raymond Bertino pulled national poison-center call logs from 2009 through 2024 and found that cannabis exposure cases in children under 6 — meaning a call came in because a toddler got into an edible, a vape pen, or loose flower — climbed from 132 cases in 2009 to 8,430 in 2024, a 6,386% increase. That is not a rounding error or a reporting artifact; it tracks almost exactly with the spread of legal cannabis markets and the retail packaging that comes with them. A gummy that looks like candy doesn’t know the difference between an adult’s nightstand and a toddler’s reach, and this study is the plainest evidence yet that pediatric emergency departments are absorbing a cost that legalization debates rarely price in.

Meanwhile, a much smaller and more hopeful study out of Health & Justice found that a cheap, low-tech intervention moved a number that usually resists moving. Sulaiman, Yi, and colleagues tested a peer-delivered program for people recently released from incarceration, sometimes called “returning citizens.” Someone with their own lived experience of incarceration and recovery — a peer recovery coach — guided each participant through vividly imagining a specific, personal future reward instead of a vague one, a technique called episodic future thinking. Among the 40 people in the trial, how steeply someone devalues a bigger reward later in favor of a smaller one right now, a pattern psychologists call delay discounting and tie closely to impulsivity and to returning to use, dropped in the intervention group. The practical scaffolding that lowers relapse risk — stable housing, social support, a sense of purpose, what researchers group together as protective recovery factors — increased too. Forty people is a pilot, not a mandate, but a short conversation moving a number tied to relapse risk is worth watching closely as it scales.

The practical scaffolding that lowers relapse risk — stable housing, social support, a sense of purpose, what researchers group together as protective recovery factors — increased too.

The fourth study lands closer to a warning than a fix. Magnan, Cameron, and Song showed 353 young adult e-cigarette users the FDA’s mandatory nicotine-addiction warning and measured how strongly it registered, cognitively and emotionally. People who vaped exclusively felt it more; people who used e-cigarettes and still smoked combustible cigarettes — sometimes the higher-risk group, carrying two nicotine habits instead of one — felt it less. A warning label is supposed to land hardest where the stakes are highest. Here it landed softest there instead.

None of these four studies were designed to talk to each other, and forcing a single tidy lesson out of a Medicaid claims analysis, a poison-center tally, a jail-reentry pilot, and a warning-label experiment would flatter the research more than it deserves — the kind of quiet, unglamorous work that fills our science and medicine coverage most months, rather than any single breakthrough. What connects them is smaller and less quotable: each one is a case where the number everyone expected to move, moved differently than expected, or didn’t move at all. More prescribers didn’t mean more patients. Legal cannabis didn’t come with childproofing built in. Forty people and a handful of conversations did something a decade of clinic-building couldn’t. A warning meant for the riskiest group reached everyone but them.

That is what addiction research actually looks like most months — not a breakthrough, not a scandal, just the data quietly correcting the story policymakers had already told themselves.